Biotech Values

[DewDiligence]

I do not believe that for a minute. That change will do little, if anything, to make the [US patent] system more predictable or certain.

Big Pharma / Big Bio are unanimously in favor of the changes in the new legislation; generic-drug companies initially opposed the changes, but I haven’t heard them complain lately. All told, therefore, the changes are probably bullish for drug/biotech investors.